Given our current era of legisilation, pharmaceutical industry greed and big insurance companies, it makes sense that big issues end up at the Supreme Court. This session will include two major issues - U.S. Supreme Court weighs any-willing-provider laws: The high court's roster of medically related concerns also includes a look at Medicaid drug rebate programs

When the high court starts its new session in October, it will examine whether states' efforts to ensure that qualified physicians and other health professionals don't get shut out of health plan networks are preempted by the federal Employee Retirement Income and Security Act of 1974.

Justices also will look at how far states can go in trying to use their Medicaid programs to negotiate prescription drug rebates with pharmaceutical companies for non-Medicaid-eligible residents. The court may add other health-related cases to its docket as its new term approaches.